{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-000524","form_type":"8-K/A","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.415233+00:00","generated_at":"2026-05-23T22:40:39.537692+00:00","sec_items":["3.01","5.02","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Virpax receives Nasdaq delisting notice; all independent directors and CFO resign","bullets":["Nasdaq panel delists Virpax for failing minimum stockholders' equity; trading suspended April 4, 2025.","Company will not appeal; delisting effective after SEC Form 25 filing.","Four directors (Randhawa, Deol, Su, Field) resigned effective April 2, 2025.","Katharyn Field also resigned as VP; Usama Chaudhry resigned as CFO, same date.","Resignations not due to any disagreement with company per filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-000524","json":"https://secwatch.observer/filing/0001731122-25-000524.json","markdown":"https://secwatch.observer/filing/0001731122-25-000524.md","text":"https://secwatch.observer/filing/0001731122-25-000524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/e6490_8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:40:39.537692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc04ea0d6027fce654122f1653d9f338651d58b1","claim":"Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"81a4dafb9f","claim":"Esha Randhawa resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"9e8e652402","claim":"Usama Chaudhry resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On the same date, Ms. Field also resigned from her position as Vice President, and Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, each effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ca07de9140","claim":"Judy Su resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"caab1cc827","claim":"Charn Deol resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"ecd6c1d7cb","claim":"Katharyn Field resigned as Vice President at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On the same date, Ms. Field also resigned from her position as Vice President, and Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, each effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President"}],"fact_type":"executive_change"},{"claim_id":"f16b0e02f2","claim":"Katharyn Field resigned as Member of the Board of Directors at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On April 2, 2025, Esha Randhawa, Charn Deol, Judy Su, and Katharyn Field each resigned from their positions as members of the Board of Directors of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}